Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity by Hong Qin, Soung-chul.

Slides:



Advertisements
Similar presentations
Hybrid Tumor Vaccines David L. Liu, MD, PhD Professor of Surgery and Oncology Tumor Immunotherapy Division RedSun Institute 242 Dorchester Street, Boston,
Advertisements

Cancer Vaccines Medicines that belong to a class of substances known as biological response modifiers. Biological response modifiers stimulate or restore.
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity by Francesca S. Gazzaniga,
Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus- tumor activity without exacerbating graft-versus-host.
Who is the best donor for a related HLA haplotype-mismatched transplant? by Yu Wang, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Xiao-Hui Zhang,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Volume 5, Issue 3, Pages (March 2002)
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
The beauty of TLR agonists for CTCL
by Peter Ruf, and Horst Lindhofer
Do HSCs divide asymmetrically?
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens by Helene Pere, Yves Montier, Jagadeesh.
Collaboration is required for successful immunotherapy
“Vitamin hypothesis”: explanation for allergy increase?
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell.
Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice by Robert G. Newman,
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Rituximab-induced tumor cell agglutination
How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Human TSLP promotes CD40 ligand-induced IL-12 production by myeloid dendritic cells but maintains their Th2 priming potential by Norihiko Watanabe, Shino.
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
An Unusual Cause of Abdominal Pain in Sickle Cell Disease
Engineering regulatory T cells against factor VIII inhibitors
Protease inhibitors potentiate chemotherapy-induced neutropenia
Setting the table for macrophages
Taking a leaf from the book of oral tolerance
Has the T cell bitten off more than it can chew?
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Has MRD monitoring superseded other prognostic factors in adult ALL?
Lymphoma spread? Target CD47-SIRPα!
Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity by Mikael Maksimow, Mari.
Volume 15, Issue 8, Pages (August 2007)
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,
Volume 134, Issue 5, Pages (May 2008)
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.
Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.
Vaccinating Against Helicobacter pylori: Dissecting the Mechanism
Chung-Han Lee, Roman Yelensky, Karin Jooss, Timothy A. Chan 
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Volume 13, Issue 1, Pages (January 2006)
by Hannah L Bader, Tracy Pritchett, and Tien Hsu
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.
Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.
Cartoon of OV-mediated effects in tumor.
Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
Presentation transcript:

Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity by Hong Qin, Soung-chul Cha, Sattva S. Neelapu, Yanyan Lou, Jinsong Wei, Yong- Jun Liu, and Larry W. Kwak Blood Volume 114(19): November 5, 2009 ©2009 by American Society of Hematology

Administration of myotoxins at vaccination sites significantly enhanced idiotype DNA vaccine- induced tumor protection. Hong Qin et al. Blood 2009;114: ©2009 by American Society of Hematology

Prophylactic antitumor effects of additional DNA vaccines were significantly improved by the combined vaccination therapy. Hong Qin et al. Blood 2009;114: ©2009 by American Society of Hematology

The combined vaccination therapy elicited memory and therapeutic antitumor immunity. Hong Qin et al. Blood 2009;114: ©2009 by American Society of Hematology

Combined cardiotoxin and DNA vaccine elicited potent, T cell–dependent, tumor antigen– specific immunity. Hong Qin et al. Blood 2009;114: ©2009 by American Society of Hematology

Anti-idiotype antibody response was not required for the vaccine-induced tumor protection. Hong Qin et al. Blood 2009;114: ©2009 by American Society of Hematology

Cardiotoxin administration recruits antigen-presenting cells and converts nonimmunogenic, unfused antigen into a protective vaccine. Hong Qin et al. Blood 2009;114: ©2009 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.